|
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
A nomogram incorporating radiomics signature, IDH and age improved the performance of OS estimation, which might be a new complement to the treatment guidelines of glioma.
|
31606714 |
2019 |
|
Glioma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Several alterations like <i>IDH1/2</i> mutations that interfere with "epigenetic modifier" enzymes, the mutations of the histone 3 variants H3.1 and H3.3 that alter the global H3K27me3 levels and the altered expression of histone methyltransferases and demethylases are considered potentially druggable targets in glioma and molecules targeting these alterations are being tested in preclinical and clinical trials.
|
30386738 |
2018 |
|
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Among IDH-wildtype gliomas, an even higher portion (44.4%, 67/151) showed significantly larger BTVs in the early summation images, which was observed in 5.3% (5/94) of IDH-mutant gliomas only: most of the latter had significantly smaller BTVs in the early summation images, i.e.
|
29487977 |
2018 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Analysis of Raman spectra revealed increased intensities in spectral bands related to DNA in IDH1 mutant glioma while bands assigned to molecular vibrations of lipids were significantly decreased.
|
29761368 |
2018 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The Student's t test and Mann-Whitney U test were used to evaluate differences in parameters of DWI and 3D pCASL between low and high grade as well as between mutant and wild-type IDH1 diffuse gliomas; receiver operator characteristic (ROC) analysis was used to assess the diagnostic performance.
|
29777252 |
2018 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We recently established that miRNAs are components of the IDH1 mutant-associated glioma CpG island methylator phenotype (G-CIMP) and specifically identified MIR148A as a tumor-suppressive miRNA within G-CIMP.
|
29545476 |
2018 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
IDH1 mutation (mIDH1) occurs in 20-30% of gliomas and is a promising target for the cancer therapy.
|
29290542 |
2018 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These results indicate that G0S2 is epigenetically silenced in IDH1-mutant glioma.
|
30388142 |
2018 |
|
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
5-Hydroxymethylcytosine (5hmC) is implicated in glioma pathogenesis; however, its role in IDH1 mutant gliomas is incompletely understood.
|
29428975 |
2018 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the isocitrate dehydrogenase (IDH) enzyme affect 40% of gliomas and represent a major diagnostic and prognostic marker.
|
29126125 |
2018 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Taken together, these results underscore the functional importance of IDH1 mutation heterozygosity in glioma biology and indicate functional loss of mutant IDH1 as an escape mechanism underlying glioma progression and the pathway of redox homeostasis as potential therapeutic targets.
|
29288440 |
2018 |
|
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The current study aimed to perform a comprehensive meta-analysis to investigate the correlation of isocitrate-dehydrogenase 1 (IDH1), an important molecular biomarker for glioma classification and prognosis, to preoperative seizure incidence in LGG.
|
29414139 |
2018 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Here, using human astrocyte and glioma tumorsphere systems, we generate a large-scale atlas of mutant-IDH1-induced epigenomic reprogramming.
|
29180699 |
2018 |
|
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to quantitatively evaluate the diagnostic efficiency of NODDI in tumour parenchyma (TP) and peritumoural area (PT) for grading gliomas and detecting isocitrate dehydrogenase-1 (<i>IDH-1</i>) mutation status.
|
30023167 |
2018 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The single nucleotide polymorphism (SNP) rs11554137 (IDH1<sup>105GGT</sup>) at codon 105 of IDH1 has been reported in patients with several tumor types, including those with glioma.
|
29535392 |
2018 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Thus, we have uncovered a mechanism by which tumor cell survival may be promoted in conditions associated with perturbed redox homeostasis, as occurs in IDH1-mutated glioma.
|
29562167 |
2018 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We found that IGFBP2 expression was upregulated in high-grade glioma and GBM and downregulated in IDH mutant glioma.
|
29721393 |
2018 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These data support the possibility of a functional tricarboxylic acid cycle that runs in reductive manner, as a probable mechanism of action of bevacizumab in IDH1 mutated gliomas and propose a new target pathway for effective treatment of malignant gliomas.
|
30511933 |
2018 |
|
Glioma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
GPR158 promotes glioma stem cell differentiation and induces apoptosis and is highest expressed in the cerebral cortex and in oligodendrogliomas, lower in IDH mutant astrocytomas and lowest in the most malignant form of glioma, IDH wild-type glioblastoma.
|
29720725 |
2018 |
|
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Mutations in isocitrate dehydrogenase 1 (IDH1) drive most low-grade gliomas and secondary glioblastomas and many chondrosarcomas and acute myeloid leukemia cases.
|
30249606 |
2018 |
|
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
p-Hsp27 is a novel biomarker of glioma and might have important clinical value for further classification of patients with wild-type IDH1 and normal ATRX expression, for evaluating prognosis and for guidance for adjuvant therapy.
|
29550762 |
2018 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These findings support further research into IDH mutations, and the potential for an antiepileptic therapeutic effect of their inhibitors, in patients with glioma-associated epilepsy.
|
29172136 |
2018 |
|
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Mutant isocitrate dehydrogenase 1 (IDH1) is an attractive therapeutic target for the treatment of various cancers such as AML, glioma, and glioblastoma.
|
30034612 |
2018 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The data demonstrate that IDH1 mutation reduces the malignant progression of glioma by causing a less aggressive phenotype of GSCs which are involved in the Wnt/β‑catenin signaling.
|
29115585 |
2018 |
|
Glioma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The expression level of B7-H3 was consistently up-regulated in IDH wild-type glioma and highly enriched in mesenchymal subtype.
|
30377558 |
2018 |